Merkel Cell Carcinoma

P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting

Cells were then subjected to combined treatment with inhibitors and cisplatin (CDDP), and viability and ROS levels were further analyzed. Our results clearly illustrate that cells treated with NNMT inhibitors underwent significant reductions in viability, increased ROS production and activation of apoptotic pathways. Given the association of NNMT with cancer aggressiveness, inhibiting its catalytic activity might present a novel strategy for counteracting cancer growth and chemoresistance, providing the rationale for an effective anti-cancer therapy based on the use of specific NNMT inhibitors.

Despite not containing a consensus E2 site, we detected weak E2F binding to the NCCRs of BKPyV and SV40, suggesting that E2Fs also contribute to transcription of their early genes. Overall, our findings challenge the existing paradigm of PyV infection, that LT expression activates E2F signaling via RB1 inhibition, and suggest that E2Fs must already be active in the PyV-infected host cell for LT/ST expression and viral replication.

This region appears to be critical for helping the virus maintain latency by fine-tuning the host's response. Our findings provide new insight into how MCPyV may regulate early infection dynamics and suggest that identifying functional domains such as LIT could help guide future approaches to study viral persistence and its contribution to MCC.

P1/2, N=31, Terminated, Transgene | N=48 --> 31 | Trial completion date: Apr 2025 --> Oct 2025 | Recruiting --> Terminated | Trial primary completion date: Apr 2025 --> Oct 2025; Sponsor decision following completion of Phase I part not driven by safety reason

P=N/A, N=15, Recruiting, Assistance Publique - Hôpitaux de Paris | Not yet recruiting --> Recruiting

MCC is a highly malignant cutaneous neuroendocrine carcinoma, requiring the combination of pathological morphology examination and immunophenotyping to confirm the diagnosis. Moreover, the primary MCC treatment of surgical treatment should be supplemented with chemotherapy and/or local radiotherapy to alleviate its poor prognosis, easy recurrence or metastasis, and high mortality.

This report highlights the importance of careful evaluation and timely surgical intervention of pelvic masses. It also emphasizes that rare conditions such as ovarian strumal carcinoid should be taken into account when evaluating atypical ovarian tumors.

Altogether, Piwil-2 poses a poor prognosticator in MCCs, which is linked to MCC oncogenesis and SOX-2. Further research is needed to better understand underlying mechanisms and to prove their clinical relevance.

Monitoring is based on regular clinical and radiological follow-up over several years. Biomarkers such as NSE and anti-MCPyV serology are currently being evaluated.

MCC oncogenesis and treatment response transcend viral status. While mutational analysis confirms previous findings, assessment of the transcriptome and tumor microenvironment suggests alternate therapeutic targets.

Recently, the advent of programmed cell death protein 1 axis agents has improved outcomes in metastatic disease. There are ongoing clinical trials evaluating these agents in resected disease.